Persistent and robust antibody responses to ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine observed in Ugandans across varied baseline immune profiles.

Persistent and robust antibody responses to ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine observed in Ugandans across varied baseline immune profiles.

Understanding SARS-CoV-2 vaccine-induced antibody responses in varied antigenic and serological prior exposures can guide optimal vaccination strategies for enhanced immunogenicity. We evaluated spike (S)-directed IgG, IgM, and IgA antibody optical densities (ODs) and concentrations to the two-dose...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jennifer Serwanga, Gerald Kevin Oluka, Claire Baine, Violet Ankunda, Jackson Sembera, Laban Kato, Joseph Ssebwana Katende, Geoffrey Odoch, Betty Oliver Auma, Ben Gombe, COVID-19 Immunoprofiling Team, Monica Musenero, Pontiano Kaleebu
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2024-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0303113
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Impact of ChAdOx1 nCoV-19 (Covishield™) Vaccination: How Long Will It Persist?
by: Leimapokpam Sumitra Devi, et al.
Published: (2022-01-01)

Two cases of adult-onset de novo immunoglobulin A vasculitis with nephritis: Post-Covishield (ChAdOx1 nCoV-19; Oxford–Astra Zeneca) vaccination
by: Vijoy Kumar Jha, et al.
Published: (2022-01-01)

Two Cases of Immune Thrombocytopenia (ITP) Related to Viral Vector Vaccination ChAdOx1-S (AstraZeneca) and a Good Response after Thrombopoietin Receptor Agonist (TPO-RA) Therapy
by: Konstantina Salveridou, et al.
Published: (2024-09-01)

Cutaneous Leukocytoclastic Vasculitis after ChAdOx1 nCoV-19 Vaccine
by: Mansoor C. Abdulla
Published: (2022-10-01)

Design, Immunogenicity and Preclinical Efficacy of the ChAdOx1.COVconsv12 Pan-Sarbecovirus T-Cell Vaccine
by: Edmund G.-T. Wee, et al.
Published: (2024-08-01)

New-Onset rheumatoid arthritis following ChAdOx1 nCoV-19 vaccine administration
by: Bhupen Barman, et al.
Published: (2022-01-01)

Transcriptomic and miRNA Signatures of ChAdOx1 nCoV-19 Vaccine Response Using Machine Learning
by: Jinting Lin, et al.
Published: (2025-06-01)

IgA vasculitis post-ChAdOx1 nCoV-19 vaccine in a patient with rheumatoid arthritis
by: Kunal Chandwar, et al.
Published: (2022-01-01)

Hemophagocytic Lymphohistiocytosis after ChAdOx1 nCoV-19 Coronavirus Vaccination in a Patient with no Known Comorbidities
by: Nitin Rai, et al.
Published: (2022-10-01)

Acquired Thrombotic Thrombocytopenic Purpura After ChAdOx1 nCoV-19 Vaccine: A Case Report
by: Domenica Caramazza, et al.
Published: (2022-07-01)

Thrombosis with thrombocytopenia after first dose of ChAdOx1 nCoV-19 vaccine: a case report
by: K. Kolodynskaja, et al.
Published: (2021-12-01)

A Case of De Novo Antineutrophil Cytoplasmic Autoantibody Associated Glomerulonephritis Following ChAdOx1 Vaccination in an Indian Metropolitan City
by: Harshad Limaye, et al.
Published: (2023-01-01)

A Case of De Novo Antineutrophil Cytoplasmic Autoantibody Associated Glomerulonephritis Following ChAdOx1 Vaccination in an Indian Metropolitan City
by: Harshad Limaye, et al.
Published: (2023-01-01)

Age differences in immunity to human seasonal coronaviruses and the immunogenicity of ChAdOx1 nCoV-19 (AZD1222)Research in context
by: Sandra Belij-Rammerstorfer, et al.
Published: (2025-08-01)

Guillain–Barré Syndrome Post COVID-19 Vaccination with ChAdOx1 nCoV-19 Vaccine: A Colombian Case Report
by: Isabel Cristina Hurtado, et al.
Published: (2023-01-01)

Good recovery of immunization stress-related responses presenting as a cluster of stroke-like events following CoronaVac and ChAdOx1 vaccinations.
by: Metha Apiwattanakul, et al.
Published: (2022-01-01)

Longitudinal Comparison of Three T-Cell Assays and Three Antibody Assays Against SARS-CoV-2 Following Homologous mRNA-1273/mRNA-1273/mRNA-1273 and Heterologous ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naïve Healthcare Workers
by: Hyeyoung Lee, et al.
Published: (2024-11-01)

Humoral immune response to an mRNA-1273 booster after chAdOx1-nCoV-19-priming among patients undergoing hemodialysis
by: Bo-Yu Cheng, et al.
Published: (2023-01-01)

ChAdOx1 nCoV-19 vaccine and its self-reported adverse events: a cross-sectional study from Western Nepal
by: Arun Gautam, et al.
Published: (2021-07-01)

WCN24-1865 LONG-TERM IMMUNOGENICITY AND EFFICACY OF RECOMBINANT ChAdOx1 nCoV- 19 CORONA VIRUS VACCINE (COVISHIELD) IN PATIENTS ON HEMODIALYSIS – A PROSPECTIVE, 1-YEAR FOLLOW-UP COHORT STUDY
by: Aarthi Muthukumaran, et al.
Published: (2024-04-01)

Effectiveness of AstraZeneca vaccine against SARS-CoV-2 (ChAdox1-S) in reducing in-hospital mortality in individuals with COVID-19 and schizophrenia: A retrospective cohort study
by: Tiffany Dyu, et al.
Published: (2024-12-01)

Memory B cell proliferation drives differences in neutralising responses between ChAdOx1 and BNT162b2 SARS-CoV-2 vaccines
by: David Hodgson, et al.
Published: (2025-03-01)

Safety and utilisation of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine: a UK post-authorisation active surveillance study
by: Miranda Davies, et al.
Published: (2025-05-01)

Comparing ChAdOx1 nCoV-19 Coronavirus Vaccine (Recombinant) (Covishield) and BBV152; Bharat Biotech COVID-19 Vaccine (Covaxin) for COVID-19: Reports of Adverse Events Following Vaccination among the Indian Population
by: Sukhpal Kaur, et al.
Published: (2025-01-01)

Profile of Humoral Immunity and B Cell Pool in Infection with the SARS-CoV-2 Prototype Strain and AZD1222 (ChAdOx nCoV-19) Vaccination
by: Débora Familiar-Macedo, et al.
Published: (2025-01-01)

A rare case of superior ophthalmic vein thrombosis and thrombocytopenia following ChAdOx1 nCoV-19 vaccine against SARS-CoV-2
by: Irina Panovska-Stavridis
Published: (2021-06-01)

Effectiveness of ChAdOx1 nCoV-19 (Vaxzevria) primary series vaccine against SARS-CoV-2 beta and delta variants: a nationwide study
by: Hiam Chemaitelly, et al.
Published: (2025-08-01)

Serosurveillance among healthcare workers vaccinated with ChAdOx1 nCoV-19 Corona vaccine in a tertiary hospital of Kerala, India: prospective cohort studу
by: S. K. Njarekkattuvalappil, et al.
Published: (2021-10-01)

Single ChAdOx1 nCoV‐19 dose elicits stronger immune response in previously infected individuals than in SARS‐CoV2 naive persons
by: Fawzi Ebrahim, et al.
Published: (2024-01-01)

Antibody Response against SARS-CoV-2 Following ChAdOx1(Astezeneca AZD 1222) Vaccine in Health Care Workers in a Tertiary Care Hospital in India
by: Felice FAIZAL, et al.
Published: (2021-09-01)

Fulminant Vaccine-Induced Immune Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 (AZD1222) Vaccine Administration in a Woman with Obesity: A Case Report
by: Yian-Lin Chou, et al.
Published: (2024-04-01)

Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil
by: Sue Ann Costa Clemens, MD, PhD, et al.
Published: (2025-08-01)

Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England.
by: William N Whiteley, et al.
Published: (2022-02-01)

Influence of previous COVID-19 exposure and vaccine type (CoronaVac, ChAdOx1 nCov-19 or BNT162b2) on antibody and cytokine (Th1 or Th2) responses
by: Diana Lourdes Padilla-Bórquez, et al.
Published: (2024-12-01)

Real-World Effectiveness of COVID-19 Vaccines (ChAdOx-1s, CoronaVac, BBIBP-CorV, mRNA-1273, and BNT162b2) in Jakarta: Protocol for Test-Negative Design of Health Care Data
by: Erlina Burhan, et al.
Published: (2025-04-01)

Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults
by: Prasad S. Kulkarni, et al.
Published: (2024-12-01)

First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales.
by: Steven Kerr, et al.
Published: (2022-02-01)

Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: A test-negative design case-control study.
by: Thiago Cerqueira-Silva, et al.
Published: (2023-01-01)

Durability of immune response against omicron BA.2 and BA.4/5 and T cell responses after boosting with mRNA and adenoviral vector-based vaccines following heterologous CoronaVac/ChAdOx-1nCov-19 vaccination
by: Nungruthai Suntronwong, et al.
Published: (2023-12-01)

Relationships and Activities. The study is supported by OOO AstraZeneca Pharmaceuticals.
by: E. V. Shlyakhto, et al.
Published: (2023-07-01)